share_log

3: Initial statement of beneficial ownership of securities-Director Fry Simon Jeremy

SEC ·  Dec 21, 2024 06:10

Summary by Moomoo AI

Simon Jeremy Fry has been appointed as a Director of Conduit Pharmaceuticals Inc, effective December 18, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Fry directly owns 200,000 shares of Conduit Pharmaceuticals' common stock. This substantial shareholding suggests a significant commitment to the company and aligns the new director's interests with those of other shareholders.The Form 3 was signed by Fry on December 20, 2024, two days after the event requiring the statement. No derivative securities were reported in the filing, indicating that Fry's ownership is currently limited to common stock.
Simon Jeremy Fry has been appointed as a Director of Conduit Pharmaceuticals Inc, effective December 18, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Fry directly owns 200,000 shares of Conduit Pharmaceuticals' common stock. This substantial shareholding suggests a significant commitment to the company and aligns the new director's interests with those of other shareholders.The Form 3 was signed by Fry on December 20, 2024, two days after the event requiring the statement. No derivative securities were reported in the filing, indicating that Fry's ownership is currently limited to common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated